BioTrack Capital
博远资本
BioTrack Capital (博远资本) is a China-based institutional investor active in healthcare and biotech venture deals. In the most recent reporting, it participated as a follow-on investor in Aureka Biotechnologies' $35 million Series A+ round in April 2026, alongside Sequoia China and Matrix Partners China . Earlier that same year it joined the $150 million Series B for Syneron Bio, a macrocyclic peptide drug developer, in a round co-led by Decheng Capital and CDH VGC . The fund also appears in 2025 coverage of Minghui Pharma's $131 million pre-IPO round, listed among new institutional backers alongside 5Y Capital and New Day Fund . Beyond these disclosed positions, elsewhere's corpus does not yet capture fund size, vintage, or team background for BioTrack.
AI-generated — may contain errors, please verify.
Coverage
5Y News | Xunming Life Sciences Closes Tens of Millions of Dollars in Series A+ Funding
Accelerating the construction of next-generation Tech-Bio agent infrastructure.
五源资本·5Y News | Syneron Bio Closes $150 Million Series B Round
Syneron Bio today announced the completion of its Series B funding round.
五源资本·5Y News｜Minghui Pharma Closes $131 Million Pre-IPO Round to Accelerate Pipeline Development and Global Expansion
Dedicated to developing innovative therapies that address unmet clinical needs worldwide.
五源资本·
